An approach to transfusion and hemorrhage in trauma: current perspectives on restrictive transfusion strategies.
Hemorrhagic shock is a leading cause of death in trauma patients. Surgical control of bleeding and fluid resuscitation with both crystalloid and blood products remain the mainstay of therapy for injured patients with bleeding. However, there has been a recent re-evaluation of transfusion practice. Both the fear of transmissible disease and the costs of transfusing blood products have led to increasingly restrictive transfusion practices. A small percentage of trauma patients require massive transfusion. These patients are complex and difficult to manage, and clinicians must act quickly to save them. There is little evidence to help guide clinical transfusion decisions in these patients. A rational approach to using blood products requires an understanding of the end points of resuscitation. Resuscitation with fluids and red cells is necessary to improve perfusion and oxygen delivery to tissues. Avoiding overtransfusion is key, however, because transfusion is also associated with significant risks. This trend toward reducing allogenic blood exposure will likely continue. New technologies that have the potential of reducing blood loss and transfusion requirements in trauma patients with massive bleeding are being developed, and similar old technologies are being reapplied.
Tien
Homer
H
Canadian Forces Health Service, Department of National Defense, Toronto, Ont, Canada.
Nascimento
Bartolomeu
B
Callum
Jeannie
J
Rizoli
Sandro
S
D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D015718:Fibrin Tissue Adhesive; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy*; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D007552:Isotonic Solutions / Q000627:therapeutic use; D010952:Plasma Substitutes / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012151:Resuscitation; D013916:Thrombelastography; D065227:Transfusion Reaction; D014947:Wounds and Injuries / Q000150:complications / Q000628:therapy*
D015718:Fibrin Tissue Adhesive; D006490:Hemostatics; D007552:Isotonic Solutions; D010952:Plasma Substitutes; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa